Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of caspofungin in severely burned patients
2007-006767-69Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2008
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in burn injury and invasive mycoses, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: AUC0-24h of caspofungin, Cmax of caspofungin and 1 more. Started Jun 2008; status: active.
02
Drugs
caspofungin
03
Conditions
burn injuryinvasive mycoses
Beyond the preview
Go deeper on 2007-006767-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006767-69.